bbo-8520
·Code: BBO-8520
bbo-8520: developed by 1 company · 1 clinical trial tracked.
bbo-8520 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect bbo-8520 to BBOT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could bbo-8520 → BBOT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Phase 1 |
Clinical Trials (1)
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
Primary endpoint: Adverse Events
Interventionalopen350 targetStarted 2024-05Completion 2031-0935 sites · Australia, Canada, Denmark, Spain…TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Frequently asked questions
Who is developing bbo-8520?
bbo-8520 is being developed by BridgeBio Oncology Therapeutics, Inc..
How many clinical trials involve bbo-8520?
BioSniper tracks 1 clinical trial involving bbo-8520.